11. Pharmacological screening identified promising combination partners in marginal zone lymphoma models with secondary resistance to BTK and PI3K inhibitors. (October 2022) Authors: Arribas, A.; Vultaggio, S.; Andronache, A.; Robusto, M.; Fancelli, D.; Cannas, E.; Spriano, F.; Tarantelli, C.; Rossi, D.; Zucca, E.; Stathis, A.; Varasi, M.; Mercurio, C.; Bertoni, F. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S108 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
12. PQR309, idelalisib, duvelisib and ibrutinib lead to similar gene expression changes in activated B-cell like (ABC) diffuse large B-cell lymphoma (DLBCL). (December 2016) Authors: Arribas, A.; Rinaldi, A.; Spriano, F.; Tarantelli, C.; Gaudio, E.; Bernasconi, E.; Hillmann, P.; Kwee, I.; Stathis, A.; Fabbro, D.; Stüssi, G.; Zucca, E.; Rossi, D.; Cmiljanovic, V.; Bertoni, F. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S39 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
13. SIMULTANEOUS BET/CREBBP/EP300 TARGETING APPROACH COMPARED TO SINGLE BET OR CREBBP/EP300 INHIBITION IN DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL). (12th June 2019) Authors: Spriano, F.; Gaudio, E.; Tarantelli, C.; Golino, G.; Cascione, L.; Zucca, E.; Stathis, A.; Giles, F.; Bertoni, F. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 512 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
14. The anti-CD205 antibody drug conjugate MEN1309/OBT076 shows synergistic activity in combination with the monoclonal antibody rituximab in diffuse large B cell lymphomas. (October 2022) Authors: Tarantelli, C.; Civanelli, E.; Gaudio, E.; Stathis, A.; Merlino, G.; Binaschi, M.; Bertoni, F. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S89 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
15. THE ANTIBODY‐DRUG CONJUGATE (ADC) LONCASTUXIMAB TESIRINE (ADCT‐402) TARGETING CD19 SHOWS STRONG IN VITRO ANTI‐LYMPHOMA ACTIVITY BOTH AS SINGLE AGENTS AND IN COMBINATION. (12th June 2019) Authors: Tarantelli, C.; Spriano, F.; Golino, G.; Gaudio, E.; Scalise, L.; Cascione, L.; Zucca, E.; van Berkel, P.; Stathis, A.; Zammarchi, F.; Bertoni, F. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 129 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
16. The antimetabolite KAT/3BP has in vitro and in vivo anti-lymphoma activity. (October 2022) Authors: Tarantelli, C.; Spriano, F.; Civanelli, E.; Arribas, A.J.; Aresu, L.; Risi, G.; Kayali, O.; Stathis, A.; Ko, Y.H.; Bertoni, F. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S65 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
17. THE ANTI‐CD25 ANTIBODY‐DRUG CONJUGATE CAMIDANLUMAB TESIRINE (ADCT‐301) PRESENTS A STRONG PRECLINICAL ACTIVITY BOTH AS SINGLE AGENT AND IN COMBINATION IN LYMPHOMA CELL LINES. (12th June 2019) Authors: Spriano, F.; Tarantelli, C.; Golino, G.; Gaudio, E.; Scalise, L.; Cascione, L.; Zucca, E.; Van Berkel, P.; Stathis, A.; Zammarchi, F.; Bertoni, F. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 323 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
18. The BET bromodomain inhibitor (BET-i) BAY 1238097: Mechanism of action and pre-clinical activity in diffuse large B-cell lymphoma (DLBCL). (December 2016) Authors: Bernasconi, E.; Gaudio, E.; Lejeune, P.; Tarantelli, C.; Rinaldi, A.; Kwee, I.; Mensah, A.A.; Chung, E.Y.L.; Stathis, A.; Ocker, M.; Zucca, E.; Haendler, B.; Bertoni, F. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S84 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
19. The first-in-class WASP activator EG-011 is active in lymphoma and multiple myeloma cell lines resistant to FDA approved compounds. (October 2022) Authors: Spriano, F.; Arribas, A.J.; Tarantelli, C.; Sartori, G.; Gaudio, E.; Driessen, C.; Bertoni, F. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S107 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
20. THE FIRST‐IN‐CLASS ETS INHIBITOR TK‐216 INTERFERES WITH ETS TRANSCRIPTION FACTORS AND SYNERGIZE WITH LENALIDOMIDE IN LYMPHOMA. (12th June 2019) Authors: Spriano, F.; Chung, E.; Napoli, S.; Tarantelli, C.; Gaudio, E.; Cascione, L.; Cavalli, A.; Rinaldi, A.; Kwee, I.; Ye, H.; Rossi, D.; Zucca, E.; Stathis, A.; Jessen, K.; Lannutti, B.; Toretsky, J.; Bertoni, F. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 322 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗